{"authors": [["Morgan", "Alwena H", "AH", "Molecular Neurobiology, Institute of Life Science, Medical School, Swansea University, UK."], ["Rees", "Daniel J", "DJ", "Molecular Neurobiology, Institute of Life Science, Medical School, Swansea University, UK."], ["Andrews", "Zane B", "ZB", "Biomedicine Discovery Institute & Department of Physiology, Monash University, Melbourne, Victoria, Australia."], ["Davies", "Jeffrey S", "JS", "Molecular Neurobiology, Institute of Life Science, Medical School, Swansea University, UK. Electronic address: jeff.s.davies@swansea.ac.uk."]], "doi": "10.1016/j.neuropharm.2017.12.027", "date": "2018-01-16_23:18:28", "journal": ["Neuropharmacology", "Neuropharmacology"], "year": null, "title": "Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?", "id": "29277488", "text": ["parkinson", "disease", "common", "neurodegenerative", "disorder", "affecting", "10", "million", "people", "worldwide", "mechanisms", "underlying", "pathogenesis", "still", "unclear", "disease", "characterised", "dopamine", "nerve", "cell", "loss", "accumulation", "results", "motor", "dysfunction", "review", "discuss", "neuroprotective", "effects", "stomach", "hormone", "ghrelin", "models", "parkinson", "disease", "recent", "findings", "suggest", "may", "modulate", "mitochondrial", "function", "autophagic", "clearance", "impaired", "organelle", "response", "changes", "cellular", "energy", "balance", "consider", "putative", "cellular", "mechanisms", "underlying", "possible", "role", "ghrelin", "mimetics", "slowing", "preventing", "parkinson", "disease", "progression"]}